conbercept + triamcinolone

Conbercept + triamcinolone is a combination therapy involving the intravitreal administration of two agents for ocular diseases, particularly those characterized by neovascularization and macular edema. Conbercept is a recombinant fusion protein that acts as an anti–vascular endothelial growth factor (VEGF) agent, binding multiple VEGF isoforms and placental growth factor to inhibit pathological angiogenesis and reduce vascular permeability. Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory and antiangiogenic properties; it suppresses proinflammatory cytokines and VEGF expression, thereby reducing retinal inflammation and edema. This combination has been studied in conditions such as diabetic macular edema (DME), wet age-related macular degeneration (wAMD), branch retinal vein occlusion–related macular edema (BRVO-ME), and proliferative diabetic retinopathy, especially in cases where monotherapy response is suboptimal[3][4][6]. The rationale for combining these drugs lies in their complementary mechanisms—conbercept primarily targets abnormal blood vessel growth while triamcinolone addresses inflammation—potentially offering enhanced efficacy over either agent alone.

Brand names

Lumitin (for conbercept)

Other names

conbercept plus triamcinolone acetonideIVC + IVTA (intravitreal conbercept plus intravitreal triamcinolone acetonide)